UBN
Urbanise.Com Limited
π¦πΊ ASX
π€ TECHNOLOGY
π Overview
π Performance
π΅ Cost
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
-9.33%
Annual Growth
5 years average annual growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
0
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Urbanise.com Ltd designs and develops cloud-based Software as a Service (SaaS) platform for the property sector, specifically Strata and Facilities Management. The company is headquartered in North Sydney, New South Wales. The company went IPO on 2014-09-22. Its segments include Strata and Facilities. The company specializes in delivering cutting-edge proptech solutions through its two platforms: Urbanise Strata and Urbanise FM. The Strata platform manages the communications and accounting functions for apartment buildings, strata commercial towers and large housing communities. The Facilities Management platform manages the repair and maintenance for infrastructure, buildings, residential and commercial properties. Urbanise Strata serves strata managers in administering strata schemes and jointly owned properties. Urbanise FM software aids facilities managers in property asset maintenance and contractor supervision. Its client base spans across 17 countries with over 600,000 lots managed on Urbanise Strata and 2.2 million assets managed on Urbanise FM.
π Performance
Price History
-96.33%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$0.44
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in UBN
0
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in UBN
N/A
UBN investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
πΆ Age of investors
18 - 25
26 - 34
35 - 90
π Legal gender of investors
Female
Male
Pearlers who invest in UBN also invest in...
Want more shares? Try these...
Uscom Ltd. engages in the development, design, manufacture, and marketing of non-invasive cardiovascular and pulmonary medical devices. The company is headquartered in Sydney, New South Wales. The company went IPO on 2003-12-10. The company specializes in the development and marketing of non-invasive cardiovascular and pulmonary medical devices. The company has three suites of devices in the field of cardiac, vascular, and pulmonary monitoring: the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. The USCOM 1A is a non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities, and is used to guide treatment. The USCOM 1A device has applications in emergency, intensive care medicine and anesthesia. The Uscom BP+ is a supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms in the heart, as well as in the arm, information only previously available using invasive cardiac catheterization. Its VENTITEST digital ultrasonic ventilator testing solution is a new system for testing ventilators.
π Performance (5Yr p.a)
-14.12%
π Share price
$0.03 AUD
π©Ί HEALTH CARE
Universal Biosensors, Inc. engages in the research, development and manufacture of medical diagnostics test systems for point-of-care professional and home use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-12-13. The firm is engaged in developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, womenβs health and fertility, non-human and environmental testing using its platform technology and hand-held point-of-use devices. Its core technology consists of a disposable, multi-layer test strip, which incorporates an electrochemical sensing system using opposing electrodes that detect specific analytes in samples as small as a droplet. Its products include Sentia Wine Analyzer, Xprecia Prime Coagulation Analyzer, Hemostasis Reference Laboratory (HRL) and PETRACKR Veterinary Blood Glucose Monitoring System. HRL supports contract research organizations, central laboratories, early phase clinics, pharmaceutical/ biotechnology companies and academic researchers conducting clinical trials. HRL offers multiplex cytokine analysis on the MESO QuickPlex SQ 120MM technology platform.
π Performance (5Yr p.a)
-7.57%
π Share price
$0.12 AUD
π©Ί HEALTH CARE